Volume 355, Issue 9212, Pages (April 2000)

Slides:

Advertisements

Similar presentations

Volume 376, Issue 9753, Pages (November 2010)

Advertisements

Volume 370, Issue 9586, Pages (August 2007)

Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of.

Volume 357, Issue 9257, Pages (March 2001)

Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international,

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO

Volume 8, Issue 10, Pages (October 2009)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Volume 11, Issue 4, Pages (April 2012)

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Copyright © 2012 American Medical Association. All rights reserved.

Volume 376, Issue 9734, Pages (July 2010)

From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann.

Volume 373, Issue 9679, Pages (June 2009)

From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann.

Volume 378, Issue 9804, Pages (November 2011)

Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y

Meta-analysis of randomised controlled trials

Volume 5, Issue 4, Pages (April 2006)

Volume 366, Issue 9503, Pages (December 2005)

Volume 376, Issue 9734, Pages (July 2010)

Volume 13, Issue 3, Pages (March 2012)

Volume 392, Issue 10145, Pages (August 2018)

Volume 11, Issue 6, Pages (June 2010)

Volume 382, Issue 9891, Pages (August 2013)

Cervical disc arthroplasty for symptomatic cervical disc disease: Traditional and Bayesian meta-analysis with trial sequential analysis Shun-Li Kan,

Volume 14, Issue 4, Pages (April 2015)

A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both Nadia Aissaoui, Edith Martins,

Succinct Review of the New VTE Prevention and Management Guidelines

Aspirin in the prevention of cancer – Author's reply

George E. Kikano, MD, Marie T. Brown, MD Mayo Clinic Proceedings

Volume 373, Issue 9663, Pages (February 2009)

Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants Matthew R.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Volume 373, Issue 9679, Pages (June 2009)

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Volume 375, Issue 9722, Pages (April 2010)

Venous Thromboembolism and Antithrombotic Therapy in Pregnancy

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Volume 9, Issue 9, Pages (September 2010)

Meta-analysis of randomised controlled trials

Volume 386, Issue 10001, Pages (October 2015)

Volume 379, Issue 9822, Pages (March 2012)

Volume 12, Issue 6, Pages (June 2013)

PATHWAY-2: spironolactone for resistant hypertension – Authors' reply

Adrian Martineau The Lancet Respiratory Medicine

Volume 375, Issue 9709, Pages (January 2010)

Volume 376, Issue 9753, Pages (November 2010)

Errata The Lancet Infectious Diseases

Volume 393, Issue 10172, Pages (February 2019)

Volume 371, Issue 9627, Pages (May 2008)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Volume 382, Issue 9894, Pages (August 2013)

Volume 140, Issue 7, Pages (June 2011)

Volume 373, Issue 9658, Pages (January 2009)

Department of Error The Lancet Volume 369, Issue 9564, (March 2007)

Volume 375, Issue 9719, Pages (March 2010)

Volume 379, Issue 9822, Pages (March 2012)

ACST: which subgroups will benefit most from carotid endarterectomy?

Medically unexplained symptom management

Volume 11, Issue 3, Pages (March 2010)

Volume 373, Issue 9672, Pages (April 2009)

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28.

Volume 368, Issue 9541, Pages (September 2006)

Volume 73, Issue 8, Pages (April 2008)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

Clive Kearon, Michael J Kovacs, Jim A Julian

Volume 373, Issue 9680, Pages (June 2009)

Presentation transcript:

Volume 355, Issue 9212, Pages 1295-1302 (April 2000) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial The Lancet Volume 355, Issue 9212, Pages 1295-1302 (April 2000) DOI: 10.1016/S0140-6736(00)02110-3 Copyright © 2000 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet 2000 355, 1295-1302DOI: (10.1016/S0140-6736(00)02110-3) Copyright © 2000 Elsevier Ltd Terms and Conditions

Figure 2 Proportional effects of aspirin on pulmonary embolism and symptomatic deep-vein thrombosis after hip fracture Black squares=point estimates (with area proportional to number of events) and horizontal lines=95% CI for observed effects in different subgroups. Diamonds=point estimates and 95% CI for overall effects, with proportional reductions indicated alongside. Solid vertical line=hazard ratio of 1·0 (ie, no effect of treatment), and dotted vertical line=observed overall effect. Any venous thromboembolism refers to numbers of patients with deep-vein thrombosis, pulmonary embolism, or both (ie, avoids double-counting of any patients with more than one such event). The Lancet 2000 355, 1295-1302DOI: (10.1016/S0140-6736(00)02110-3) Copyright © 2000 Elsevier Ltd Terms and Conditions

Figure 3 Absolute effects of aspirin on pulmoary embolism and deep-vein thrombosis after hip fracture The Lancet 2000 355, 1295-1302DOI: (10.1016/S0140-6736(00)02110-3) Copyright © 2000 Elsevier Ltd Terms and Conditions

Figure 4 Proportional effects of aspirin on pulmonary embolism and symptomatic deep-vein thrombosis in various subgroups of hip-fracture patients. Conventions as in figure 2. UF=unfractionated standard heparin; LMW=low-molecular-weight heparin. Denominators for subgroups defined by week of follow-up (open squares) are all patients alive at start of each follow-up period. The Lancet 2000 355, 1295-1302DOI: (10.1016/S0140-6736(00)02110-3) Copyright © 2000 Elsevier Ltd Terms and Conditions

Figure 5 Proportional effects of antiplatelet therapy on venous thromboembolism in previous meta-analysis and PEP trial *Only symptomatic deep-vein thrombosis recorded in PEP trial. Conventions as in Figure 2. Reference 17 provided results for previous meta-analysis. In most trials in that meta-analysis, patients were roughly evenly assigned antiplatelet therapy or control, but in some, more were deliberately assigned to active treatment. To allow direct comparisons of percentages observed to have an event in each treatment group, adjusted totals were given after converting any uneven randomised trials to even ones by counting the control groups more than once. Statistical calculations were, however, based on stratified analyses of actual numbers from individual trials (unadjusted controls in previous meta-analysis: 761/2316 for deep-vein thrombosis and 117/4216 for pulmonary embolism). The Lancet 2000 355, 1295-1302DOI: (10.1016/S0140-6736(00)02110-3) Copyright © 2000 Elsevier Ltd Terms and Conditions